Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 124,360 shares of the biopharmaceutical company's stock, valued at approximately $29,263,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.10% of Alnylam Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 4.0%

NASDAQ ALNY traded up $11.69 on Friday, reaching $304.59. 3,116,157 shares of the stock traded hands, compared to its average volume of 929,720. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a fifty day moving average price of $260.38 and a 200-day moving average price of $255.08. The company has a market cap of $39.71 billion, a price-to-earnings ratio of -140.36 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 12 month low of $147.25 and a 12 month high of $306.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Bank of America raised their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. Finally, Scotiabank raised their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.